Prevention of cisplatin nephrotoxicity (CN) in head and neck cancer patients receiving concurrent chemoradiation (CCRT) by adding oral rehydration solution (ORS) to short hydration regimen: A randomized open-label controlled trial.

被引：0

作者：

Maisrikrod, Aungsumal

Sakdejayont, Siwat

Rongmuang, Jakkapan

Sathitruangsak, Chirawadee

Sunpaweravong, Patrapim

Dechaphunkul, Arunee

机构：

[1] Prince Songkla Univ, Hat Yai, Hat Yai, Thailand

[2] Prince Songkla Univ, Fac Med, Holist Ctr Canc Study & Care, Div Med Oncol,Dept Internal Med, Hat Yai, Songkhla, Thailand

[3] Prince Songkla Univ, Songklanagarind Hosp, Hat Yai, Thailand

[4] Prince Songkla Univ, Fac Med, Dept Internal Med, Hat Yai, Thailand

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e18560

引用

页数：2

共 10 条

[1] The effect of eicosapentaenoic acid in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy in an outpatient clinic: An open-label prospective randomized trial.
Chang, J. T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.
Huang, He
Feng, Yanling
Wan, Ting
Zhang, Yanna
Cao, Xinping
Huang, Yongwen
Xiong, Ying
Huang, Xin
Zheng, Min
Li, Yanfang
Li, Jundong
Chen, Guandi
Li, Hu
Chen, Yile
Ma, Liguo
Yang, Hongying
Li, Li
Yao, Shuzhong
Liu, Qing
Liu, Jihong
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients
Ingargiola, Rossana
De Santis, Maria Carmen
Iacovelli, Nicola Alessandro
Facchinetti, Nadia
Cavallo, Anna
Ivaldi, Eliana
Dispinzieri, Michela
Franceschini, Marzia
Giandini, Carlotta
Romanello, Domenico Attilio
Di Biaso, Simona
Sabetti, Michela
Locati, Laura
Alfieri, Salvatore
Bossi, Paolo
Guglielmo, Mauro
Macchi, Fabio
Lozza, Laura
Valdagni, Riccardo
Fallai, Carlo
Pignoli, Emanuele
Orlandi, Ester
RADIATION ONCOLOGY, 2020, 15 (01)
[4] A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients
Rossana Ingargiola
Maria Carmen De Santis
Nicola Alessandro Iacovelli
Nadia Facchinetti
Anna Cavallo
Eliana Ivaldi
Michela Dispinzieri
Marzia Franceschini
Carlotta Giandini
Domenico Attilio Romanello
Simona Di Biaso
Michela Sabetti
Laura Locati
Salvatore Alfieri
Paolo Bossi
Mauro Guglielmo
Fabio Macchi
Laura Lozza
Riccardo Valdagni
Carlo Fallai
Emanuele Pignoli
Ester Orlandi
Radiation Oncology, 15
[5] Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis
Antunes, Heliton S.
Herchenhorn, Daniel
Small, Isabele A.
Araujo, Carlos M. M.
Pais Viegas, Celia Maria
Ramos, Gabriela de Assis
Dias, Fernando L.
Ferreira, Carlos G.
ORAL ONCOLOGY, 2017, 71 : 11 - 15
[6] Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
Bonomi, Marcelo Raul
Sher, David
Blakaj, Dukaglin
Kabarriti, Rafi
Colvett, Kyle
Oronsky, Bryan
Sonis, Stephen T.
Bianco, James A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment
A. Lozano
J. Marruecos
J. Rubió
N. Farré
J. Gómez-Millán
R. Morera
I. Planas
M. Lanzuela
M. G. Vázquez-Masedo
L. Cascallar
J. Giralt
G. Escames
V. Valentí
P. Grima
R. Bosser
C. Tarragó
R. Mesía
Clinical and Translational Oncology, 2021, 23 : 1801 - 1810
[8] Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment
Lozano, A.
Marruecos, J.
Rubio, J.
Farre, N.
Gomez-Millan, J.
Morera, R.
Planas, I.
Lanzuela, M.
Vazquez-Masedo, M. G.
Cascallar, L.
Giralt, J.
Escames, G.
Valenti, V.
Grima, P.
Bosser, R.
Tarrago, C.
Mesia, R.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (09): : 1801 - 1810
[9] A Phase IIb, 4 Arm Open-label, Randomized Trial, to Assess the Safety and Efficacy of Concurrent hR3 Monoclonal Antibody against EGF-receptor with Chemoradiation Therapy or with Radiation Therapy in Patients with Advanced (Stage III-IVa), Inoperable Head and Neck Cancer
Viswanath, L.
Reddy, K. B. K. M.
Vidyasagar, M.
Koteshwar, R.
Shenoy, A. M.
Thimmaiah, N.
Babu, G.
Joseph, B.
Bapsy, P. P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S15 - S16
[10] Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)
Bruemmendorf, T.
Guigay, J.
Mesia, R.
Trigo, J.
Keilholz, U.
Dittrich, C.
Kerber, A.
Picard, M.
Vermorken, J.
EJC SUPPLEMENTS, 2009, 7 (02): : 475 - 476

← 1 →